Core Insights - Yisheng Pharmaceutical reported that as of September 10, 2025, the total number of shareholders is 20,399 [2] Company Summary - Yisheng Pharmaceutical is actively engaging with investors through interactive platforms [2] - The company is tracking its shareholder base, indicating a focus on investor relations and transparency [2]

Summary of Key Points Core Viewpoint - Yisheng Pharmaceutical reported a decrease in the number of shareholders and a decline in both revenue and net profit for the first half of the year, indicating potential challenges for the company moving forward [2]. Shareholder Information - As of August 31, the number of shareholders for Yisheng Pharmaceutical was 20,554, a decrease of 1,366 from the previous period (August 20), representing a decline of 6.23% [2]. Stock Performance - The closing price of Yisheng Pharmaceutical was 8.08 yuan, reflecting an increase of 1.38%. However, since the concentration of shares began, the stock price has cumulatively decreased by 6.05%, with 2 days of increase and 6 days of decrease during the reporting period [2]. Financial Performance - For the first half of the year, Yisheng Pharmaceutical achieved a revenue of 328 million yuan, a year-on-year decrease of 5.75%. The net profit was 18.76 million yuan, down 43.71% year-on-year. The basic earnings per share were 0.0567 yuan, and the weighted average return on equity was 0.84% [2].

Group 1 - A new company named Hangzhou Youxuan Youyi Health Management Co., Ltd. has been established, with Cui Dongsheng as the legal representative [1] - The company's business scope includes the acquisition of primary agricultural products, sales of agricultural and sideline products, wholesale of edible agricultural products, and retail of edible agricultural products [1] - The company is jointly held by Jiao Ge Peng You Xuan Technology Co., Ltd. and Yisheng Pharmaceutical (002566) among others [1]

Financial Performance - Yisheng Pharmaceutical (002566) reported a net profit decline of 43.71% year-on-year for the first half of 2025, with total revenue of 328 million yuan, down 5.75% from the previous year [1] - The gross profit margin decreased to 75.15%, a drop of 2.02% year-on-year, while the net profit margin fell to 6.05%, down 36.94% [1] - The company’s total expenses (selling, administrative, and financial) reached 219 million yuan, accounting for 66.83% of revenue, an increase of 2.16% year-on-year [1] Cash Flow and Financial Ratios - The company experienced a significant increase in financial expenses by 502.37% due to reduced interest income [3] - The net cash flow from investment activities increased by 100.86%, attributed to higher cash recovered from investments compared to the previous year [3] - The company’s return on invested capital (ROIC) was reported at 2.08%, indicating historically weak capital returns [3] Accounts Receivable and Inventory - The accounts receivable to profit ratio reached 312.96%, suggesting potential issues with cash collection [4] - The inventory to revenue ratio stood at 241.32%, indicating a high level of inventory relative to sales [4] Strategic Focus - The company plans to increase its research and development efforts to meet market demands, addressing concerns about the lack of new product development in traditional Chinese medicine [5]

Core Points - The company has not distributed cash dividends or bonus shares during the reporting period [3] - The company has implemented a rectification plan to address issues related to shareholding by proxy, ensuring accurate disclosure of shareholder information [5] - The board of directors and supervisory board have both approved the 2025 semi-annual report, confirming its compliance with legal and regulatory requirements [10][12] Company Overview - The company is identified as Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. with the stock code 002566 [1] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [6][7] Financial Information - The company has not reported any preferred shareholders or related data during the reporting period [8] - The company has not issued any bonds that are still in existence as of the date of the semi-annual report [9]

Core Viewpoint - Yisheng Pharmaceutical announced the approval of its 2025 semi-annual report and summary by the company's ninth board of directors during its second meeting [2] Group 1 - The announcement was made on the evening of August 22 [2] - The report includes financial performance and operational highlights for the first half of 2025 [2]

Core Viewpoint - Yisheng Pharmaceutical announced the approval of its 2025 semi-annual report and summary by the second meeting of the ninth supervisory board [2] Group 1 - The announcement was made on the evening of August 22 [2] - The report includes financial performance and operational updates for the first half of 2025 [2]

Core Insights - Yisheng Pharmaceutical (002566) reported that as of August 20, 2025, the total number of shareholders is 21,920 [1] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder statistics [1]

Core Viewpoint - Yisheng Pharmaceutical reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 328 million yuan, a year-on-year decrease of 5.75% [1] - The net profit attributable to shareholders was 18.76 million yuan, down 43.71% compared to the previous year [1] - Basic earnings per share were 0.0567 yuan, reflecting a decline of 43.69% year-on-year [1] Dividend Policy - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves [1]

Core Viewpoint - The board of directors of Jilin Province Jianshan Yisheng Pharmaceutical Co., Ltd. convened its second meeting of the ninth session on August 22, 2025, to review and approve the 2025 semi-annual report and its summary [1][2]. Group 1 - The meeting was attended by all 9 directors, and the resolutions were passed with unanimous consent (9 votes in favor, 0 against, 0 abstentions) [1]. - The meeting was legally valid and complied with the provisions of the Company Law and the Articles of Association [1]. - The full text of the 2025 semi-annual report is available on the designated information disclosure website, Juchao Information Network [1].